ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1202

Harnessing MicroRNA and Machine/Deep Learning for Early Prediction of Knee Osteoarthritis Structural Progression

Afshin Jamshidi1, Osvaldo Espin-Garcia2, Thomas G. Wilson3, Ian Loveless3, Jean-Pierre Pelletier1, Amanda Ali4 and Johanne Martel-Pelletier1, 1Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, 2Department of Epidemiology and Biostatistics, University of Western Ontario; Dalla Lana School of Public Health and Department of Statistical Sciences, University of Toronto; Department of Biostatistics, Schroeder Arthritis Institute; Krembil Research Institute, University Health Network, Toronto, ON, Canada, 3Henry Ford Health + Michigan State University Health Sciences, Detroit, MI, 4Henry Ford Health + Michigan State University Health Sciences; Center for Molecular Medicine and Genetics, Wayne State University, Montreal, QC, Canada

Meeting: ACR Convergence 2024

Keywords: Biomarkers, Micro-RNA, Osteoarthritis, prognostic factors, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Osteoarthritis – Clinical Poster I

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The development of knee osteoarthritis (OA) is generally characterized by a slow evolution. However, its progression and severity may occur rapidly in some individuals. Conventional methodologies are ineffective in predicting the knee OA progression speed. Stratification of OA patients early during the disease process is key to achieving optimal disease management. Circulating biomarkers have the potential to enable such classification, and microRNAs (miRNAs) show promise. This work aims to develop a miRNA predictive model for identifying knee OA structural progressors using miRNA as inputs combined with integrated machine/deep learning.

Methods: Baseline serum of 456 miRNAs from 152 Osteoarthritis Initiative (OAI) participants were sequenced. Participants were assigned a label for their probability of being knee structural progressors/non-progressors based on our published machine learning algorithm,1 which utilized three baseline features from MRI and two from X-rays. The development of the present prediction model first included a feature dimensionality reduction through the VarClusHi clustering. Next, the identification of the top miRNAs and OA risk factors (age, sex, body mass index, and race) predictive of knee structural progression using a comprehensive evaluation of eight machine-learning models. Prediction optimization was conducted by exploring an array of machine/deep learning models to achieve the highest area under the curve (AUC), accuracy, sensitivity, and specificity. Validation of the final prediction model included the Monte Carlo cross-validation and the evaluation of baseline plasma (30) from a different OAI cohort than for the modelling.

Results: The clustering of the original 456 miRNAs resulted in a reduced dataset of 107 miRNAs, exhibiting a low level of multicollinearity. For the model development, 152 sera were used to select the top features in forecasting knee OA structural progressors. The Elastic Net algorithm showed superior performance (AUC: 0.83; accuracy: 0.83; sensitivity: 0.82; specificity: 0.85) with a predictive model of ten features comprising seven miRNAs and three risk factors. Optimization of the predictive model was performed with an Artificial Neural Network, which exhibited excellent performance with five features, including age and the miRNAs, hsa-miR-556-3p, hsa-miR-3157-5p, hsa-miR-200a-5p, and hsa-miR-141-3p (AUC: 0.94; accuracy: 0.84; sensitivity: 0.89; specificity: 0.75). Validation with the cross-validation and an independent cohort further confirmed the model’s robustness and generalizability (AUC: 0.92, 0.81; accuracy: 0.85, 0.83; sensitivity: 0.84, 0.71; specificity: 0.88, 0.94, respectively).

Conclusion: This work introduces a novel miRNA prognosis model for knee OA patients at risk of structural progression. The developed model, requiring five baseline features, demonstrating excellent performance, and validated with an independent cohort, could have high clinical relevance to guide decision-making and hold promise for a translational application in personalized therapeutic monitoring.
1. Jamshidi A, et al. Ther Adv Musculoskelet Dis 2020;12:1-12


Disclosures: A. Jamshidi: None; O. Espin-Garcia: None; T. Wilson: None; I. Loveless: None; J. Pelletier: ArthroLab Inc., 11; A. Ali: None; J. Martel-Pelletier: ArthroLab Inc., 11.

To cite this abstract in AMA style:

Jamshidi A, Espin-Garcia O, Wilson T, Loveless I, Pelletier J, Ali A, Martel-Pelletier J. Harnessing MicroRNA and Machine/Deep Learning for Early Prediction of Knee Osteoarthritis Structural Progression [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/harnessing-microrna-and-machine-deep-learning-for-early-prediction-of-knee-osteoarthritis-structural-progression/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/harnessing-microrna-and-machine-deep-learning-for-early-prediction-of-knee-osteoarthritis-structural-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology